Clinical Trial Supplies Market: Current Analysis and Forecast (2022-2028)

Clinical Trial Supplies Market: Current Analysis and Forecast (2022-2028)

The clinical trial supplies market is a segment of the pharmaceutical and biotechnology industry that provides a wide range of products and services necessary for the conduct of clinical trials. These products and services include, but are not limited to, laboratory equipment, medical devices, pharmaceuticals, and biological samples. The clinical trial supplies market is a rapidly growing industry, driven by the increasing demand for new and innovative treatments for various diseases and conditions. The market is also influenced by advances in technology, which have made it easier and more efficient to conduct clinical trials.

The Clinical Trial Supplies Market is expected to grow at a strong CAGR of 7% during the forecast period owing to the surge in the demand for biologics drugs. The number of biologics and temperature-sensitive drugs in clinical trials has seen a significant increase. Currently, 38.0% of pharmaceutical drugs and 35.0% of late-phase pharmaceutical drugs are biologics, and this number is expected to grow in the future due to the decreased adverse effects compared to traditional treatments for temperature-sensitive drugs. This rise in the number of biologics in clinical trials is expected to drive the demand for cold chain facilities. It is estimated that by 2022, 8 out of the top 10 biopharmaceutical products will require cold chain facilities, and the growing demand for biosimilars in both developing and developed economies will further boost the cold chain supply, contributing to the growth of the market over the forecast period.

• Based on the phase, the market is segmented into phase-I, phase-II, phase-III, and phase-IV. The phase-I is anticipated to witness high CAGR during the forecast period. The COVID-19 pandemic has led to a significant increase in the number of clinical trials for its treatment and prevention, particularly in the phase I trials. For instance, in March 2021, Pfizer Inc. initiated phase-I clinical trial to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.
• By services, the market is categorized in manufacturing, storage & distribution, supply chain management, and comparator sourcing. The supply chain management held a significant share of the market in 2021. The supply chain management segment is a critical component of the clinical trial supplies market, as it plays a key role in ensuring the success of clinical trials. The efficient management of supplies and materials is essential to ensure that clinical trials are conducted in a timely and cost-effective manner, and that the safety and well-being of trial participants are protected.
• Based on end use, the market is categorized into pharmaceutical, biologics, medical device, and others. The biologics category is anticipated to grow with a significant CAGR during the forecast period. In recent years, the use of biologics such as hormones, blood products, vaccines, genes, insulin, and monoclonal antibody (mAb) products has increased as advanced therapies for the treatment of diseases like Crohn's disease, rheumatoid arthritis, and other autoimmune diseases. The increased widespread use has led to significant growth in the biologics market over the forecast period. The rapid increase in the number of cancer cases is also driving the growth of the biologics market. Biologics therapy is becoming increasingly popular as it uses the body's immune systems and abilities to fight cancer or heal healthy tissue after treatment. For instance, the Journal of Global Oncology reported that biologics accounted for an overall 55% of the total expenditure on antineoplastic drugs in the healthcare system. As a result, the higher incidence of cancer cases is expected to drive the growth of the biologics market.
• Based on therapeutic use, the market is categorized into oncology, CNS, cardiovascular, infectious disease, metabolic disorders, dermatology, ophthalmology, and others. The oncology segment held a dominant share of the market in 2021. The oncology segment has a large and active R&D pipeline, with many new drugs and treatments in development. This pipeline includes a wide range of therapies, including targeted therapies, immunotherapies, and others. The development of new drugs and treatments is expected to drive the growth of the oncology segment in the clinical trial supplies market.
• For a better understanding of the market adoption of the clinical trial supplies industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the dominant share of the market and is expected to do so even in the forecast period. North America clinical trial supplies market is driven by a number of factors, including the high number of clinical trials being conducted in the region, the increasing demand for new and innovative treatments, and the presence of a large number of pharmaceutical and biotechnology companies. According to the Center for Information and Statistics on Clinical Research, there were over 59,000 clinical trials registered in the US in 2020. Further, North America is home to the largest number of projects in Phase 2 trials in 2020, which has resulted in significant investments in R&D by both industry and non-industry sponsors. For instance, in the clinical trials logistics survey conducted in 2021, it was found that approximately 60% of Phase 2 trials are outsourced. This is due to the high concentration of pharmaceutical leaders in the region, which has driven the development of innovative combinations of approved and novel treatments, resulting in a higher number of Phase 2 trial studies.
• Some of the major players operating in the market include Thermo Fisher Scientific; Catalent, Inc.; Parexel; Almac Group; Marken; Piramal Pharma Solutions; Inizio; Recipharm; Myonex; Rubicon Research Pvt. Ltd..

The clinical trial supplies market is expected to grow at a strong CAGR of around 7% during the forecast period. The growth of the clinical trial supplies market is being driven by several factors, including the significant increase in R&D expenditure by pharmaceutical and biopharmaceutical companies, the increasing number of registered clinical trials, and the trend towards decentralization of clinical trials. As reported by the Congressional Budget Office in 2021, the pharmaceutical industry has significantly increased its investment in R&D over the past two decades, with expenditures reaching 83 billion in 2019 - a 10-fold increase from the 1980s. Additionally, the number of new drug approvals has risen significantly, with a peak of 50 novel approvals by the Food and Drug Administration (FDA) in 2021. This increase in R&D expenditure and the growth of the pharmaceutical industry has had a positive impact on the clinical trial supplies market.

Some of the major players operating in the Thermo Fisher Scientific; Catalent, Inc.; Parexel; Almac Group; Marken; Piramal Pharma Solutions; Inizio; Recipharm; Myonex; Rubicon Research Pvt. Ltd.. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst therapeutic use, the cardiovascular segment to grow with high CAGR during the forecast period”

Based on the therapeutic use, the market is categorized into oncology, CNS, cardiovascular, infectious disease, metabolic disorders, dermatology, ophthalmology, and others. The cardiovascular segment is anticipated to grow with a significant CAGR during the forecast period. According to the World Health Organization, cardiovascular diseases are the leading cause of death across the globe. Cardiovascular diseases results in around 17.9 million deaths each year, globally. The major causes of cardiovascular diseases include high consumption of salt in the diet, increased consumption of tobacco, rising prevalence of smoking, and higher alcohol consumption. Thus, there is a growing need for new treatments and drugs to prevent and treat these diseases. As a result, there is a high demand for clinical trial supplies used in the development and testing of new drugs and treatments for cardiovascular diseases.

“Amongst phase, the phase-III category held a significant share of the market in 2021”

By the phase, the market is segmented into phase-I, phase-II, phase-III, and phase-IV. The phase-III dominated the market in 2021. Phase III clinical trials are the most complex of all clinical trial phases. Although the number of drugs being tested in this phase is relatively low, the complexity involved in this phase is at its highest. The failure rate in this phase is the highest due to the need for complex dosing at an optimal level, a large sample size, and a well-designed study. This high failure rate and the associated financial and human losses are a major concern. To mitigate these risks, an efficient supply chain and logistics system is essential, which is expected to drive market growth.

“Amongst end use, the pharmaceutical category held a significant share of the market in 2021”

By end use, the market is categorized into pharmaceutical, biologics, medical device, and others. The pharmaceutical held a significant share of the market in 2021. The pharmaceutical segment is expected to dominate the clinical trial supplies market during the forecast period. This is due to the high number of clinical trials being conducted for the development of new drugs and treatments by pharmaceutical companies. The clinical trial supplies used in pharmaceuticals include items such as syringes, vials, ampoules, tubes, needles, caps, and other consumables. The increasing number of clinical trials being conducted by pharmaceutical companies for the development of new drugs and treatments is expected to drive the demand for clinical trial supplies, which in turn is expected to drive the growth of the pharmaceutical segment. In addition, the increasing focus of pharmaceutical companies on developing drugs and treatments for chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is also expected to drive the demand for clinical trial supplies. This is because these diseases require long-term treatment and the use of a large number of clinical trial supplies.

“Asia Pacific to grow with high CAGR during the forecast period”

The Asia Pacific clinical trial supplies market is expected to witness significant growth in the coming years due to the increasing number of clinical trials in the region. The increasing collaborations between pharmaceutical companies and contract research organizations (CROs) in the region are also contributing to the growth of the market. For instance, in 2022, Merck in agreement with Wuxi National High-Tech Industrial Development Zone to significantly expand Merck’s first Asia-Pacific Mobius Single-Use manufacturing center in China. Further, in 2021, the Pfizer and AstraZeneca announced a collaboration to conduct clinical trials in the region for the development of new drugs and treatments. The collaboration is expected to provide access to a larger patient pool and to help speed up the clinical development process in the region. The increasing number of clinical trials in the region, combined with the increasing collaboration between pharmaceutical companies and CROs, is expected to provide opportunities for the growth of the market.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.